<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921984</url>
  </required_header>
  <id_info>
    <org_study_id>2013HNRT01</org_study_id>
    <nct_id>NCT02921984</nct_id>
  </id_info>
  <brief_title>Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors</brief_title>
  <official_title>Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of postoperative concurrent chemotherapy (CCT) has not been established for salivary
      gland tumors (SGTs). This prospective study was conducted to evaluate the feasibility and
      safety of customized CCT regimens based on the gene targets of SGTs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity profiles, graded according to the NCI CTCAE version 3.0</measure>
    <time_frame>up to 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>from date of enrollment until date of first documented disease progression or death from any cause, assessed up to 2 years</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Salivary Gland Tumors</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemotherapy with Docetaxel if genetic testing show that the patient should be sensitive to this drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pemetrexed arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemotherapy with Pemetrexed if genetic testing show that the patient should be sensitive to this drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemotherapy with Cisplatin if genetic testing show that the patient was nor sensitive to neither Pemetrexed nor Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel only: 80 mg/m2 on day one, every 21 days if</description>
    <arm_group_label>Docetaxel arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated radiotherapy</intervention_name>
    <description>a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks</description>
    <arm_group_label>Docetaxel arm</arm_group_label>
    <arm_group_label>Pemetrexed arm</arm_group_label>
    <arm_group_label>Cisplatin arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed only: 500 mg/m2 on day one, every 21 days</description>
    <arm_group_label>Pemetrexed arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin only: 70 mg/m2 on day one to day three, every 21 days</description>
    <arm_group_label>Cisplatin arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically proven diagnosis of a malignant salivary gland tumor of intermediate or
             high-grade

          2. Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (â‰¤ 5mm) or microscopically
             positive surgical margin

          3. Surgical resection with curative intent within 8 weeks prior to registration, with no
             evidence of gross tumor residual

          4. No evidence of distant metastases

          5. No synchronous or concurrent head and neck primary tumors

          6. Karnofsky score over 60

          7. Adequate organ function including the following:

               1. Absolute neutrophil count (ANC) &gt;= 1.5 * 10^9/l

               2. Platelets count &gt;= 100 * 10^9/l

               3. Hemoglobin &gt;= 10 g/dl

               4. AST and ALT &lt;= 2.5 times institutional upper limit of normal (ULN)

               5. Total bilirubin &lt;= 1.5 times institutional ULN

               6. Creatinine clearance &gt;= 50 ml/min

               7. Serum creatine &lt;= 1 times ULN

          8. Signed written informed consent

        Exclusion Criteria:

          1. Evidence of distant metastasis

          2. Prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior
             radiotherapy to the head and neck region

          3. Other previous cancer, except for in situ cervical cancer and cutaneous basal cell
             carcinoma

          4. Pregnant or breast-feeding females, or females and males of childbearing potential not
             taking adequate contraceptive measures

          5. Presence of an uncontrolled concomitant illness including, but not limited to, ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             or cardiac arrhythmia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guopei Zhu</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai 9th People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai ninth people's hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2016</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</investigator_affiliation>
    <investigator_full_name>Guopei Zhu</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Salivary Gland Tumors</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>concurrent chemotherapy</keyword>
  <keyword>genetic testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

